Text

Pengukuran Kualitas Hidup Pasien Kanker Sebelum dan Sesudah Kemoterapi dengan EORTC QLQ-C30 di RSUP Dr. Sardjito Yogyakarta (Quality of Life Measurement in Cancer Patients Befora and After Chemotherapy with EORTC QLQ-C30 in RSUP Dr. Sardjito Yogyakarta)

---

The research about cancer patients quality of life on before and after therapy of high emetogenic cytotostatic in RSUP Dr. Sardjito Yogyakarta by EORTC QLQ_C30 has been done. This research used cohort design with cancer patients who just the first time received cisplatin ≥ 50 mg/m2 and or its combination, and alsogot ondansetron-dexamethasone as anti-emetics. While the patients were given EORTC QLQ-C30 questionaire got cisplatin (before chemotherapy) and 5days after got cisplatin (after chemotherapy). The difference of the quality of the life will be analysed with paired t-test with 95% level of significancy. The correlation between the domains before and after chemotherapy was analysed by Person correlation test with the 95% level of significancy. We got 38 patients during 2 months withthe cancer diagnoses of cervix, nasopharyng, ovarium and lung. Generally, the quality of life was non-significantly decreasing, wherease not all the domains were decreasing. The physical, emotions, cognitive and social domains were non-significantly increasing. The decline in the quality of life was more influenced by the role domain of the patients, pain, the decline in appette and the financial difficulty. The correlation of domain in before and the chemotherapy after was recelved in the symptom (r=0.50).

---

Ketersediaan

Informasi Detail

Judul Seri

-

No. Panggil

Majalah Farmasi Indonesia:20(2):68-72

Penerbit

Yogyakarta : Puslitbang Farmasi, Badan Litbang Kesehatan., 2009

Deskripsi Fisik

-

Bahasa

ISBN/ISSN

0126-1037

Klasifikasi

-

Tipe Isi

-

Tipe Media

-

Tipe Pembawa

-

Edisi

-

Subjek

ovarian neoplasms
PULMONARY-TUBERCULOSIS-drug therapy
QUALITY OF LIFE.

Info Detail Spesifik

-

Pernyataan Tanggungjawab

-

Versi lain/terkait

Lampiran Berkas

Komentar

---

Anda harus masuk sebelum memberikan komentar